Anomaly Bio
Anomaly Bio is a Singapore-based synthetic biology startup that engineers microbes to produce functional bio-based ingredients via fermentation, serving B2B buyers in nutrition, crop protection, and personal care as a resilient alternative to volatile extraction-based supply chains.
- Company typePrivate
- Founded2022
- HeadquartersSingapore, Singapore
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Anomaly Bio does
Anomaly Bio is a Singapore-based synthetic biology startup that engineers microbes to function as micro-factories, converting simple sugars into functional bio-based ingredients via advanced fermentation. The company's core technology platform designs and optimizes metabolic pathways in microorganisms to produce high-value molecules targeting three end markets: nutrition, crop protection, and personal care — industries collectively described as multi-billion-dollar global markets exposed to geopolitical and climate-driven supply-chain disruptions. The company positions its on-demand, locally deployable biomanufacturing model (requiring only sugar, water, electricity, and a fermentation tank) as a structural replacement for extraction-based ingredient supply chains that depend on agricultural yields and trade flows.
The company was founded in 2022 by Armaan Dhanda and Samyak Baid, who met as freshmen at the National University of Singapore on S&T and NUSC scholarships respectively. Anomaly Bio's first commercial product is a vegan pet food supplement, developed under Mars Petcare's Next Generation Pet Food Program run with Big Idea Ventures. The business model centers on B2B supply of fermentation-derived ingredients to enterprise buyers across nutrition, crop protection, and personal care, with a stated long-term vision of globally distributed, on-demand ingredient manufacturing. Pricing is not publicly disclosed and is described as negotiated on a per-customer, per-ingredient basis, with planned long-term supply contracts as a recurring revenue stream.
As of the November 2025 pre-seed close, Anomaly Bio has raised US$2.6 million in equity led by Pebblebed Ventures, supplemented by over US$120,000 in non-dilutive awards (MIT Water Food Agriculture Innovation Prize 2025, WTFund Fellowship 2024, Singapore-India Hackathon grant under India's G20 initiatives 2023). The pre-seed capital is being deployed to build a dedicated laboratory and pilot-scale biomanufacturing facility in Singapore and to expand R&D headcount in metabolic engineering. The company remains pre-revenue with a team of 1-10 employees, relying on two co-founders and a strategic angel syndicate including operators from Notion, Solugen, Ecovative, CaratLane, MLB, Netmeds, and Undivided Capital.
Anomaly Bio firmographics
Firmographics- Name
- Anomaly Bio
- Legal name
- Anomaly Bio
- Website
- https://anomalybio.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Anomaly Bio is a Singapore-based synthetic biology startup that engineers microbes to produce functional bio-based ingredients via fermentation, serving B2B buyers in nutrition, crop protection, and personal care as a resilient alternative to volatile extraction-based supply chains.
- Ownership category
- akta.pro rank
Anomaly Bio industry classification
Industry- Product category
- Specialty Bio-Based Ingredients
- NAICS
- Dog and Cat Food Manufacturing (311111), Food Manufacturing (311)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Fermentation-Derived Proteins (Precision Fermentation, Biomass Fermentation) (AFAJAHAH)
- akta.pro secondary industries
- Fermentation-Derived Alternative Proteins Manufacturing (Precision Fermentation) (AFAKAGAH), Bioprocessing & Fermentation Manufacturing (Bioreactors, Scale-Up, Toll/CMO) (AFANAKAF), Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts) (CRADAOAI)
Keywords
Where Anomaly Bio is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices1 record
Markets served
Anomaly Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- Bio-based Ingredient Sales: Sale of fermentation-derived functional ingredients to B2B customers in the nutrition, crop protection, and personal care industries. Early revenue derived from a vegan pet food supplement. Production leverages the company's own pilot-scale biomanufacturing facilities.
- B2B Ingredient Supply Contracts: Long-term supply agreements with enterprise customers for bio-based functional ingredients produced via fermentation, providing a stable alternative to volatile agricultural supply chains.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Anomaly Bio product offering
Product offeringCore offering
Anomaly Bio engineers microorganisms into micro-factories that convert simple sugars into functional bio-based ingredients through advanced fermentation. Its initial commercial product is a vegan pet food supplement, with broader offerings targeted at nutrition, crop protection, and personal care ingredient buyers. Production uses only sugar, water, electricity, and a fermentation tank, enabling scalable, on-demand, location-independent biomanufacturing.
Product overview
Anomaly Bio is a biotech company that develops functional bio-based ingredients using advanced fermentation and strain engineering. They engineer microbes into micro-factories that transform simple sugars into functional ingredients for nutrition, crop protection, and personal care applications. Their core technology platform enables scalable, on-demand, and globally resilient biomanufacturing that replaces fragile extraction-based supply chains. The company initially launched a vegan pet food supplement and participates in the Mars Petcare Next Generation Pet Food Program.
Differentiator
Problem solved
Functional benefit
Products and services
- Vegan Pet Food Supplement A vegan pet food supplement developed using Anomaly Bio's engineered microbial fermentation technology, serving as the company's first commercial product and entry point into the pet nutrition vertical.
- Fermentation-Derived Bio-Based Functional Ingredients B2B functional ingredients produced via engineered microbial fermentation, designed to replace extraction-based supply chains for nutrition, crop protection, and personal care buyers using sugar, water, electricity, and a fermentation tank.
Quantifiable outcome
- US$2.6 million pre-seed funding raised, validating investor confidence in the biomanufacturing platform
- +1 more outcomes
Companies that use Anomaly Bio
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Anomaly Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Anomaly Bio partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Mars Petcare — Next Generation Pet Food ProgramcoreAnomaly Bio was accepted into Mars Petcare's Next Generation Pet Food Program prior to its seed raise, providing validation, mentorship, and funding for its vegan pet food supplement product. This program is run by Big Idea Ventures and supports alternative protein and pet nutrition innovation.
- National University of Singapore (NUS)minorBoth co-founders, Armaan Dhanda and Samyak Baid, met as freshmen at NUS in 2022 on the S&T Scholarship and NUSC International Scholarship respectively. The company received support from NUS as part of its early development.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Anomaly Bio competitors and assessment
Company assessmentDirect peers
- Air Protein: Fermentation company producing protein ingredients from CO2 and renewable electricity. Comparable as a fermentation-driven alternative ingredient producer targeting the nutrition and food verticals.
- Nature's Fynd: Fermentation-based protein producer using a proprietary microbe (Fusarium strain) to make nutritional proteins for food and personal care. Comparable fermentation platform with overlapping B2B ingredient customer base in nutrition and personal care.
- Solugen: US-based biotech that uses engineered enzymes and fermentation to produce bio-based chemicals and ingredients. Directly comparable as a precision-fermentation ingredient platform targeting industrial and consumer applications; its CTO (Sean Hunt) is also an Anomaly Bio angel investor.
- Culture Biosciences: Fermentation contract development and manufacturing organization serving synthetic biology companies. Comparable as a fermentation services platform and potential partner/complementor in the precision fermentation ingredient stack.
- Cauldron: Australia-based precision fermentation scale-up platform building distributed manufacturing capacity for bio-based products. Comparable as a fermentation infrastructure platform enabling on-demand ingredient production.
- Perfect Day: Precision fermentation company producing animal-free dairy proteins via engineered microbes. Directly comparable technology stack (microbes as micro-factories, sugar-to-functional-ingredient) and serves overlapping B2B nutrition customers.
- C16 Biosciences: Precision fermentation company producing sustainable alternatives to palm oil for personal care and food applications. Directly comparable fermentation platform targeting one of Anomaly Bio's named verticals (personal care).
- The EVERY Company: Formerly Clara Foods, uses precision fermentation to produce animal-free proteins (e.g., egg proteins, whey) for CPG and food brands. Directly comparable fermentation platform serving nutrition and ingredient customers.
- Ecovative: Mycelium-based biomaterials company using engineered biology to produce sustainable ingredients and packaging. Comparable as a biology-as-manufacturing platform replacing fragile extraction-based supply chains; its CEO (Eben Bayer) is also an Anomaly Bio angel investor.
Broad incumbents
- Ginkgo Bioworks: Large, publicly traded synthetic biology platform serving diverse end markets including nutrition, agriculture, and personal care. Comparable as a broad code biology-as-foundry platform but at vastly greater scale and capital base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Anomaly Bio social profiles
Digital presenceAnomaly Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Anomaly Bio leadership team
Management profileNumber of profiles
Profiles2 records
Anomaly Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Anomaly Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Anomaly Bio
What does Anomaly Bio do?
Anomaly Bio engineers microorganisms into micro-factories that convert simple sugars into functional bio-based ingredients through advanced fermentation. Its initial commercial product is a vegan pet food supplement, with broader offerings targeted at nutrition, crop protection, and personal care ingredient buyers. Production uses only sugar, water, electricity, and a fermentation tank, enabling scalable, on-demand, location-independent biomanufacturing.
Is Anomaly Bio a public or private company?
Anomaly Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Anomaly Bio founded?
Anomaly Bio was founded in 2022. It employs 1 to 10 people.
Where is Anomaly Bio based?
Anomaly Bio is headquartered in Singapore, Singapore, in the Asia region.
How does Anomaly Bio make money?
Two revenue lines are on record. Bio-based Ingredient Sales are the primary driver. The others are B2B Ingredient Supply Contracts.
Who are Anomaly Bio's main competitors?
Direct peers on record are Air Protein, Nature's Fynd, Solugen, Culture Biosciences, Cauldron, Perfect Day, C16 Biosciences, The EVERY Company and Ecovative. Ginkgo Bioworks is listed as a broad incumbent.
Does Anomaly Bio have an API?
No public API is recorded for Anomaly Bio.
What industry is Anomaly Bio in?
Anomaly Bio's product category is Specialty Bio-Based Ingredients. Its primary akta.pro industry code is AFAJAHAH, Fermentation-Derived Proteins (Precision Fermentation, Biomass Fermentation), with a secondary code of AFAKAGAH, Fermentation-Derived Alternative Proteins Manufacturing (Precision Fermentation). Its NAICS code is 311111 and its SIC code is 2836.